{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:15:12Z","timestamp":1790162112283,"version":"4.1.0"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2012,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To test the hypothesis that consolidation therapy with yttrium-90 (\n                      <jats:sup>90<\/jats:sup>\n                      Y) \u2013ibritumomab tiuxetan after brief initial therapy with four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated mantle-cell lymphoma would be a well-tolerated regimen that would improve outcomes compared with historical R-CHOP data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Patients \u2265 18 years old with histologically confirmed mantle-cell lymphoma expressing CD20 and cyclin D1 who had not received any previous therapy and had an Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function were eligible. The study enrolled and treated 57 patients, of whom 56 patients were eligible. Fifty-two patients (50 eligible patients) received\n                      <jats:sup>90<\/jats:sup>\n                      Y-ibritumomab tiuxetan. The study design required 52 eligible patients to detect a 50% improvement in the median time to treatment failure (TTF) compared with that reported for six cycles of R-CHOP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With 56 analyzed patients (median age, 60 years; men, 73%), the overall response rate was 82% (55% complete response\/complete response\u2013unconfirmed). With a median follow-up of 72 months, the median TTF was 34.2 months. The median overall survival (OS) has not been reached, with an estimated 5-year OS of 73% (79% for patients \u2264 age 65 years v 62% for patients &gt; age 65 years; P = .08 [log-rank test]). There were no unexpected toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      R-CHOP given for four cycles followed by\n                      <jats:sup>90<\/jats:sup>\n                      Y\u2013ibritumomab tiuxetan compared favorably with historical results with six cycles of R-CHOP in patients with previously untreated mantle-cell lymphoma. This regimen was well tolerated and should be applicable to most patients with this disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2012.42.2444","type":"journal-article","created":{"date-parts":[[2012,7,31]],"date-time":"2012-07-31T04:13:51Z","timestamp":1343708031000},"page":"3119-3126","source":"Crossref","is-referenced-by-count":72,"title":["Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90\u2013Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499"],"prefix":"10.1200","volume":"30","author":[{"given":"Mitchell R.","family":"Smith","sequence":"first","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailun","family":"Li","sequence":"additional","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Gordon","sequence":"additional","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Paietta","sequence":"additional","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero-Torres","sequence":"additional","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxin","family":"Hong","sequence":"additional","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Horning","sequence":"additional","affiliation":[{"name":"Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Hailun Li and Fangxin Hong, Dana-Farber Cancer Center, Boston, MA; Leo Gordon, Northwestern University, Chicago, IL; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Elisabeth Paietta, Montefiore Cancer Center, Bronx, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Brad S. Kahl, University of Wisconsin, Madison, WI; Ranjana Advani and Sandra J. Horning, Stanford University,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/5.suppl_1.S71"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1288"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"B6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","volume":"150","author":"Romaguera JE","year":"2010","journal-title":"Br J Haematol"},{"key":"B7","volume-title":"49th Annual Meeting of the American Society of Hematology","author":"Epner EM"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling M","year":"2005","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"B11","volume-title":"52nd Annual Meeting of the American Society of Hematology","author":"Hermine O"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2554"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8545"},{"key":"B14","doi-asserted-by":"crossref","first-page":"436s","DOI":"10.1200\/jco.2006.24.18_suppl.7560","volume":"24","author":"Zelenetz AD","year":"2006","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3089"},{"key":"B16","first-page":"1244","volume":"17","author":"Cheson BD","year":"1999","journal-title":"NCI Sponsored International Working Group. J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"B21","volume-title":"51st Annual Meeting of the American Society of Hematology","author":"Rummel MJ","year":"2009"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"B23","first-page":"118","author":"Kluin-Nelemans JC","year":"2011","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132142"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175653"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0162"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.044"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.164"},{"key":"B31","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner R","year":"2006","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl127"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1844"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2012.42.2444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T19:36:59Z","timestamp":1714246619000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2012.42.2444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,1]]},"references-count":34,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2012,9,1]]}},"alternative-id":["10.1200\/JCO.2012.42.2444"],"URL":"https:\/\/doi.org\/10.1200\/jco.2012.42.2444","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717954686.793461217","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,1]]}}}